Perrigo to sell Tysabri drug royalty to RPI for $2.85bn

Ireland-based Perrigo has signed an agreement to sell its right to the royalty stream from the global net sales of the multiple sclerosis drug Tysabri (natalizumab) to Royalty Pharma ’s (RPI) affiliate RPI Finance Trust for $2.85bn.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news